Kinase Domain Mutations Confer Resistance to Novel Inhibitors Targeting JAK2V617F in Myeloproliferative Neoplasms

Leukemia - United Kingdom
doi 10.1038/leu.2011.255
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

DNMT3A Mutations in Myeloproliferative Neoplasms

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

SRSF2 Mutations in Myelodysplasia/Myeloproliferative Neoplasms

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

Targeting Glutamine Metabolism in Myeloproliferative Neoplasms

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Targeting Glutamine Metabolism in Myeloproliferative Neoplasms

Blood Cells, Molecules, and Diseases
Molecular MedicineHematologyMolecular BiologyCell Biology
2015English

The N676D and G697R Mutations in the Kinase Domain of FLT3 Confer Resistance to the Inhibitor AC220

Haematologica
Hematology
2012English

FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

Mutations of ASXL1 Gene in Myeloproliferative Neoplasms

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Epigenetics and Mutations in Chronic Myeloproliferative Neoplasms

Haematologica
Hematology
2011English

MPL W515 L/K Mutations in Myeloproliferative Neoplasms

Egyptian Journal of Medical Human Genetics
Genetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy